# BPX-501 T Cells Infused Post Stem Cell Transplant in Pediatrics With Non-Malignant Disorders Ineligible for BPU004 Study

> **NCT03639844** · — · NO_LONGER_AVAILABLE · sponsor: **Bellicum Pharmaceuticals**

## Conditions studied

- Hurler Syndrome
- Inherited Metabolic Disorder
- Lysosomal Storage Disorder
- Metachromatic Leukodystrophy
- Inborn Errors of Metabolism

## Interventions

- **BIOLOGICAL:** rivogenlecleucel
- **DRUG:** rimiducid

## Key facts

- **NCT ID:** NCT03639844
- **Lead sponsor:** Bellicum Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** EXPANDED_ACCESS
- **Status:** NO_LONGER_AVAILABLE
- **Start date:** —
- **Primary completion:** —
- **Final completion:** —
- **Target enrollment:** — (—)
- **Last updated:** 2020-10-05


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03639844

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03639844, "BPX-501 T Cells Infused Post Stem Cell Transplant in Pediatrics With Non-Malignant Disorders Ineligible for BPU004 Study". Retrieved via AI Analytics 2026-06-26 from https://api.ai-analytics.org/clinical/NCT03639844. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*